ACM
NMRA icon

ADAR1 Capital Management’s Neumora Therapeutics NMRA Stock Holding History

ADAR1 Capital Management’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$357K Buy
210,000
+176,900
+534% +$337K 0.02% 226
2026
Q1 		$64.5K Sell
33,100
-17,500
-35% -$45.3K ﹤0.01% 296
2025
Q4 		$90.6K Buy
+50,600
New +$111K 0.01% 255
2025
Q2 		– Sell
-26,108
Closed -$26.1K – 228
2025
Q1 		$26.1K Sell
26,108
-42,500
-62% -$72.8K ﹤0.01% 193
2024
Q4 		$727K Buy
+68,608
New +$822K 0.15% 93

Other funds holding NMRA

SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $3.47B AUM 23.76% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

ADAR1 Capital Management's NMRA Position: Q2 2026 in Review

ADAR1 Capital Management increased its Neumora Therapeutics (NMRA) stake by 534% in Q2 2026, buying an estimated $337K and bringing the position to 210,000 shares worth $357K. The position accounts for 0.02% of the portfolio, ranked #226.

ADAR1 Capital Management first reported a position in NMRA in Q4 2024 and has held it in 5 quarters since. The position peaked at $727K in Q4 2024. 113 funds tracked by Wall St. Rank hold NMRA as of Q2 2026.

  • ADAR1 Capital Management held 210,000 shares of Neumora Therapeutics worth $357K as of Q2 2026.
  • ADAR1 Capital Management bought 176,900 Neumora Therapeutics shares in Q2 2026, an estimated $337K.
  • Neumora Therapeutics made up 0.02% of ADAR1 Capital Management's portfolio in Q2 2026, its #226 holding.
  • ADAR1 Capital Management first reported a position in Neumora Therapeutics in Q4 2024 and has held it in 5 quarters since.
  • ADAR1 Capital Management's Neumora Therapeutics position peaked at $727K in Q4 2024.
  • 113 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q2 2026.

Based on ADAR1 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.